Dabrafenib + trametinib
Checked 2026-09-09
BRAF V600-mutant melanoma (adjuvant 1 year or metastatic), NSCLC, anaplastic thyroid cancer and tumour-agnostic use
One cycle
every 28 daysComponents
| Drug | Dose | Route | Days | Note |
|---|---|---|---|---|
Dabrafenib Small-molecule kinase inhibitors (BRAF + MEK) | 150 mg twice daily | Oral | D1-28 | |
Trametinib Small-molecule kinase inhibitors (BRAF + MEK) | 2 mg once daily | Oral | D1-28 |
Cycles
until progression; 12 months adjuvant
28-day cycle
Emetogenicity
Low (10-30%)
G-CSF
Not routine
Notes
- Pyrexia in over half of patients: interrupt both drugs at the first fever.
- Dabrafenib induces CYP3A4 and CYP2C9: hormonal contraception may fail.
Used in
Products
Source
COMBI-d, NEJM 2014; COMBI-AD, NEJM 2017
Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.
Other regimens for these cancers
Trastuzumab deruxtecan 5.4 mg/kg
HER2-positive metastatic breast cancer second line; HER2-low or ultralow after chemotherapy or endocrine therapy; HER2-mutant NSCLC
every 21 days
Pembrolizumab + pemetrexed + platinum
Metastatic non-squamous NSCLC without EGFR/ALK alteration, first line, any PD-L1
every 21 days × 4
Pembrolizumab + carboplatin + paclitaxel
Metastatic squamous NSCLC, first line
every 21 days × 4
Nivolumab + ipilimumab + 2 cycles of platinum doublet
Metastatic NSCLC without EGFR/ALK alteration, first line
every 21 days
Osimertinib
EGFR ex19del or L858R NSCLC: first line metastatic (FLAURA), adjuvant for 3 years after resection (ADAURA), after chemoradiation (LAURA)
every 28 days
Cisplatin + vinorelbine (adjuvant)
Completely resected stage IB (4 cm or larger) to IIIA NSCLC
every 28 days × 4
Chemoradiation then durvalumab (PACIFIC)
Unresectable stage III NSCLC without progression after platinum-based chemoradiation
every 28 days × 12
Cisplatin + etoposide (EP)
Limited-stage SCLC with concurrent thoracic radiotherapy; stage III NSCLC chemoradiation; high-grade neuroendocrine carcinoma
every 21 days × 4